What were the most commonly reported adverse reactions to Onglyza 5 mg (saxagliptin hydrochloride) in placebo-controlled trials?

The most commonly reported adverse reactions to Onglyza 5 mg (saxagliptin hydrochloride), occurring in at least 5% of patients and more commonly than with placebo, were upper respiratory tract infection (7.7%), urinary tract infection (6.8%) and headache (6.5%).